Compare GameStop Corp. (GME) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Eli Lilly And Co — how do they compare? GameStop Corp. trades at $18.61 (market cap $8.44B), while Eli Lilly And Co trades at $1,215.26 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 128× GameStop Corp.'s market cap, and Eli Lilly And Co pays a 0.57% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals.
| GME | LLY | |
|---|---|---|
Market Cap | $8.44B | $1.08T |
Sector | Consumer Cyclical | Health |
52-Week High | $27.69 | $1.24K |
52-Week Low | $18.79 | $639.43 |
Enterprise Value | $4.42B | $1.13T |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $18.57, down 1.2% with bearish technical signals from moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a significant turnaround to profitability, achieving a 20.45% net income margin in 2025. Recent news highlights strategic shifts including potential partnership discussions with eBay instead of a full acquisition. Cash position strengthened to $4.77 billion following a $3.85 billion net cash inflow in 2025.
The outlook remains mixed with strong profitability improvements offset by bearish technical indicators and cautious analyst sentiment. Investment opportunity exists in the company's operational turnaround and cash-rich balance sheet, while risks include potential shareholder dilution from recent debt conversions and ongoing competitive pressures in the retail gaming sector.
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
